IJ**E**MS

Black seed oil nanoemulsion containing albendazole against protoscoleces of *Echinococcus granulosus*: An *in vivo* study on C57BL/6 mice

Fatemeh Oroojalian ^{1, 2}, Tahereh Mohammadzadeh ^{3, 4}, Ailin Ebrahimzadeh ², Peiman Alesheikh ¹, Reza Shafiei ^{5*}, Amir Amani ^{1, 2*}

¹ Natural Products and Medicinal Plants Research Center North Khorasan University of Medical Sciences, Bojnurd, Iran

² Department of Advanced Technologies, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran

³ Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

⁴ Department of Parasitology and Mycology, School of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran

⁵ Vector-borne Diseases Research Center North Khorasan University of Medical Sciences, Bojnurd, Iran

ARTICLEINFO

Article type: Original

Article history: Received: Oct 2, 2024 Accepted: Jan 18, 2025

Keywords:

Albendazole C57BL/6 mice Echinococcus granulosus Hydatid cysts Hydatidosis Nanoemulsions Nigella sativa

ABSTRACT

Objective(s): Hydatid cysts are typically treated with albendazole. Nevertheless, this drug has side effects and limited bioavailability. In this study, we aimed to explore a nanoemulsion of black seed oil to enhance the therapeutic efficacy of albendazole in mice with hydatid cysts.

Materials and Methods: The size of the prepared nanoemulsions was characterized using a Zetasizer analyzer. Additionally, the stability of the nanoemulsions was assessed after 45 days. MTT assay was used to compare the cytotoxicity of free albendazole, nanoemulsion containing albendazole, and nanoemulsion without albendazole. Furthermore, infected mice were treated with these preparations, euthanized, and subjected to autopsy examination. Cysts obtained from mice were examined for histopathological features.

Results: ALB-NE (albendazole-loaded nanoemulsion) DLS results were obtained from black seed oil. Freshly prepared ALB-NE showed (d50 = 170 nm), PDI: 0.323, ALB-NE after 45 days storage at 25 °C were (d50 = 92.4 nm), and ALB-NE after 45 days storage at 45 °C revealed (d50 = 118 nm). The cytotoxicity of albendazole was reduced when loaded into the nanoemulsion. Moreover, the group treated with nanoemulsion containing albendazole showed a significant decrease in size and number of cysts compared to those receiving free albendazole or nanoemulsion without the drug. Additionally, after 60 days, the nanoemulsion containing albendazole showed 100% survival, while the survival rate was 50% for free albendazole, 75% for nanoemulsion without albendazole, and 37.5% for PBS.

Conclusion: The nanoemulsion containing albendazole can be a promising treatment for hydatid cysts.

► Please cite this article as:

Oroojalian F, Mohammadzadeh T, Ebrahimzadeh A, Alesheikh P, Shafiei R, Amani A. Black seed oil nanoemulsion containing albendazole against protoscoleces of *Echinococcus granulosus*: An *in vivo* study on C57BL/6 mice. Iran J Basic Med Sci 2025; 28: 755-761. doi: https:// dx.doi.org/10.22038/ijbms.2025.83014.17942

Introduction

Hydatidosis, also known as cystic echinococcosis, is a parasitic disease caused by the larval stage of the dog tapeworm *Echinococcus granulosus*. Hydatidosis is widespread worldwide and is commonly endemic, where humans are close to domestic animals and canids (1, 2). The infection is transmitted when carnivores (e.g., dogs) excrete parasite eggs in their feces. Humans are infected directly (through contact with the eggs) or indirectly (e.g., ingesting contaminated raw vegetables). As a result, cysts develop in internal body organs (e.g., lungs and liver, see Figure 1) (3, 4).

Surgical removal of the cysts is the preferred treatment when cysts are large, located in the lungs, or have been infected secondarily. Alternatively, drug therapy is recommended for patients who cannot undergo surgery or have inactive, uncomplicated cysts in the liver (5-7). Broad-spectrum anthelmintics, including albendazole (ALB), mebendazole, praziquantel, and fenbendazole, are typically used for this purpose (8, 9). In particular, ALB, which inhibits the polymerization of tubulin in the larval parasite and reduces cyst size and/or causes parasite death, is a common medication. Treatment with ALB is associated with preventing recurrence and avoiding surgery (10, 11). However, its bioavailability is extremely low (< 5% in humans) (12). Additionally, ALB can cause adverse effects such as abdominal pain, nausea, vomiting, dizziness, diarrhea, liver dysfunction, leukopenia, and hematuria (11). Natural products and compounds have served as herbal remedies since the dawn of human civilization (13, 14). Phytochemicals, secondary metabolites derived from plants, possess various biological activities in humans, including potential anticancer, antibacterial, antifungal, anti-viral, and parasitic effects (15, 16). In contemporary times, a significant number of the leading pharmaceutical products

^{*}Corresponding authors: Amir Amani. Natural Products and Medicinal Plants Research Center North Khorasan University of Medical Sciences, Bojnurd, Iran, Department of Advanced Technologies, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran. Email: a.amani@nkums.ac.ir; Reza Shafiei. Vector-borne Diseases Research Center North Khorasan University of Medical Sciences, Bojnurd, Iran. Email: a.amani@nkums.ac.ir; Reza Shafiei.



© 2025. This work is openly licensed via CC BY 4.0.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Figure 1. Schematic diagram of the life cycle of Echinococcus granulosus

are either natural compounds or their derivatives (17-19). Nanoemulsions are isotropic oil, surfactant, and water mixtures with particle sizes less than or around 100 nm (20, 21). As drug carriers, they offer numerous advantages, for example, easy preparation procedure, feasibility of being produced on a large scale, protection of the drug against hydrolysis and oxidation, improving the absorption efficiency of the drug, minimizing the overall dose required, and reducing the side effects of the drug. In recent years, nanoemulsion-based carriers have received significant attention for delivering water-insoluble compounds in different administration routes, including topical (22, 23), ophthalmic (24), and inhalation (25). In oral applications, nanoemulsions can improve bioavailability, efficiency, and/or pharmacokinetics, as in the case of mebudipine (26), amlodipine (27), felodipine (28), curcumin (29), and atovaquone (30).

Black seed (*Nigella sativa*, Latin name *Niger nigella*) possesses notable pharmaceutical properties, including anticancer, anti-allergic, anti-hypertensive, anti-corruption, antibacterial, anti-parasitic, cardioprotective, and immunostimulatory effects. This plant is also beneficial in treating infections caused by intestinal worms, especially in children (31). This study assessed the effectiveness of ALB-loaded nanoemulsion prepared with black seed oil in treating hydatid cysts in C57BL/6 mice.

Materials and Methods

Tween 80, Span 80, DMEM, FBS, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) and penicillin-streptomycin (10,000 U/ml) were purchased from Sigma-Aldrich (USA). Black seed oil was prepared by cold pressing the seeds.

Preparation and characterization of black seed oil nanoemulsion

Black seed oil, Tween 80, Span 20, and ethanol were mixed (10 min, 600 rpm) at room temperature (see Table 1- supporting information). Subsequently, water was added dropwise and stirred for 45 min to obtain a clear, viscous

colloidal solution. The mixtures were kept for 24 hr (room temperature, away from light). Samples that showed any sign of phase separation, precipitation, or turbidity were discarded. The particle size was determined by dynamic light scattering (DLS, Scatteroscope I, K-ONE.LTD, Korea).

Albendazole-containing nanoemulsion (ALB-NE) was prepared by adding ALB to the mixture of oil, surfactants, and co-surfactants before adding water.

Stability of the nanoemulsions

To evaluate the stability of nanoemulsions over time, the particle size of freshly prepared nanoemulsions and those assessed 45 days post-preparation at a temperature of 25 °C was measured using a particle size analyzer. Additionally, the turbidity of the emulsions was examined visually.

In vitro cytotoxicity evaluation

The cytotoxic effects of the preparations on the L929 cell line were investigated using the MTT colorimetric assay. Mouse Fibroblast L929 Cells were purchased from Mashhad University of Medical Sciences (Mashhad, Iran). Cells were maintained in Dulbecco's Modified Eagle's Medium enriched with 10% heat-inactivated fetal bovine serum and penicillin (100 units/ml)/streptomycin (100 μ g/ml). The cultured cells were maintained in a humidified 37 °C incubator containing 5% CO₂. Before each experimentation, cells were starved with DMEM containing 0.5% FBS for 24 hr.

The cells were grown (24 hr) in 96-well plates (original density 1×10^4 cells/well) in 100 µl DMEM medium having 10% FBS (32, 33). The cells were treated with the preparation, and after 48 hr incubation, 20 µl MTT solution (5 mg/ml) was added to each well for three hr. Afterward, the medium was discarded, and DMSO (150 µl) was added to each well. A plate reader (Tecan Group Ltd. Mannedorf, Switzerland) measured the absorbance at 570 (34, 35).

Preparation of protoscoleces

The livers of sheep infected with hydatid cysts were

I**JB**MS

collected from industrial slaughterhouses in Shiraz and Tehran (Iran) and transferred to the parasitology lab. After washing the surface of the cysts with 70% ethanol, the whole hydatid fluid containing protoscoleces was drained out of the cyst in sterile conditions and transferred to a 50 ml falcon tube. Protoscoleces were then allowed to precipitate and washed three to five times with sterile normal saline. Microscopically, the viability of protoscoleces was assessed with 0.1% aqueous eosin solution. Unstained (viable) protoscoleces were used for injection into animals.

Animal studies

Forty-eight male 9-week-old C57BL/6 mice were used for the animal studies (Ethical approval code: IR.NKUMS. REC.1397.107). Twenty microliters of the protoscoleces sediment was diluted to a final volume of 0.3 ml of phosphate buffer saline (PBS) with Penicillin (100 units) and streptomycin (200 mg/ml), and injected into the peritoneal cavity of the animals (36, 37). Eight months after the injection, the mice were gavaged with either of the following treatment groups (1 ml final volume):

- Free ALB (suspension containing 50 mg/kg)

- ALB-NE (nanoemulsion containing 50 mg/kg ALB)
- NE (nanoemulsion without ALB)
- Negative control (PBS)

After three months, mice were euthanized, and the cysts were harvested and examined.

Data analysis

GraphPad Prism 8.0 software was used to analyze the data. Descriptive statistics were presented as mean \pm standard deviation (SD). A one-way ANOVA test was used to detect differences between groups. To determine group differences, we used Tukey *post hoc* pairwise comparison. *P*-value<0.05 was used to qualify the significant differences.

Results

Characterization of the nanoemulsion

Figure 2 shows the appearance of ALB-NE when freshly prepared and stored for 45 days at 25 °C and 45 °C. The preparations indicated no sign of separation phase or turbidity. The particle size results for the samples are given



Figure 3. DLS results of ALB-NE (albendazole-loaded nanoemulsion) obtained from black seed oil

A) freshly prepared ALB-NE (d50 = 170 nm), B) ALB-NE after 45 days storage at 25 °C (d50 = 92.4 nm), C) ALB-NE after 45 days storage at 45 °C (d50 = 118 nm).

in Figure 3. The findings from visual examination and DLS indicate that the nanoemulsion remains stable for a minimum of 45 days at 45 °C.

In vitro cytotoxicity

Figure 4 represents the results of the MTT assay of ALB, ALB-NE, and NE. As the details show, ALB appears to be the most cytotoxic preparation (mean \pm SD IC50 5.24 \pm 1.51 µg/ml), while NE has minimum toxicity (mean \pm SD IC50 20.51 \pm 1.12 µg/ml). The cytotoxicity of ALB-NE falls between that of the other two samples (i.e., mean \pm SD IC50 8.66 \pm 1.80 µg/ml).



Figure 2. Freshly prepared ALB-NE (albendazole-loaded nanoemulsion) (A) and after remaining at 2525 °C and 4545 °C for 45 days



Figure 4. MTT assay results of free ALB, ALB-NE (albendazole-loaded nanoemulsions), and NE (albendazole-free nanoemulsions) on L929 cells after 24 hr



Figure 5. C57BL/6 mice infected with hydatid cysts were assigned to different experimental groups ALB: free albendazole, NE: nanoemulsion without albendazole, ALB-NE: nanoemulsion containing albendazole.

In vivo studies

Figures 5 and 6 depict the results of treatment of the infected mice. The details show that cysts' size and number decreased significantly in mice receiving ALB-NE, compared with the other three groups (*P*-value<0.5). Mean±SD sizes of cysts were 0.3 ± 0.1 , 1.4 ± 0.2 , 1.3 ± 0.1 , and 1.9 ± 0.2 mm for ALB-NE, NE, ALB, and PBS treatment groups, respectively. Also, the mean±SD numbers of observed cysts were 2.3 ± 1.3 , 12.3 ± 1.7 , 12.3 ± 1.7 , and 18.0 ± 1.8 for ALB-NE, NE, ALB, and PBS treatment groups, respectively.

Figure 7 shows the survival diagram for the different treatment groups. After 60 days of treatment, ALB-NE was the only group that showed 100% survival, while other groups indicated 50% (ALB), 75% (NE), and 37.5% (PBS) survival.

Histological analysis

The pathological microscopic observation showed no protoscolex or brood capsule proliferation from the germinal layer of cysts in ALB or ALB-NE treated groups (see Figure 8). Additionally, the pathological analysis of collected cysts in the ALB-treated group showed typical germinal and laminated structures, which are well-formed layers. In contrast, parasites recovered from ALB-NE treatment exhibited changes in the germinal layer, such



Figure 6. Number (top) and size (bottom) of hydatid cysts in C57BL/6 mice across experimental groups

ALB: free albendazole, NE: nanoemulsion without albendazole, ALB-NE: nanoemulsion containing, PBS: control group. *** indicate *P*-value<0.001.

IJ**B**MS



Figure 7. Kaplan-Meier plot (survival diagram) for C57BL/6 mice infected with hydatid cysts across experimental groups

ALB: free albendazole 50 mg/kg, NE: nanoemulsion without albendazole, ALB-NE: nanoemulsion containing 50 mg/kg albendazole and PBS: control group.



Figure 8. Histopathological findings in the mice receiving free albendazole (ALB) and albendazole-loaded nanoemulsion (ALB-NE)

as breakage discontinuity and looseness. Furthermore, upon visual examination, the liver damage signs were less prominent in the group receiving ALB-NE compared with that of ALB (free albendazole).

Discussion

This study highlights the superiority of a black seed oil nanoemulsion as a vehicle in treating hydatidosis. The particle size of the nanoemulsion was below 200 nm. It is well-known that particle size > 200 nm often activates the complement system. Thus, the particles are cleared rapidly from the blood (38). Additionally, obtaining minimum 45day stability at 45 °C, while not enough for the market, can still provide sufficient stability for the study period.

The MTT assay showed free albendazole with an IC50 value of 5.12 µg/ml, comparable with a previous report (i.e., 0.69-8.1 μ g/ml, depending on the cell line) (39). The free nanoemulsion (without albendazole) had minimum cytotoxicity, arguably due to its biocompatible ingredients. When the albendazole was loaded into the nanoemulsion, the cytotoxicity increased due to the presence of albendazole as a relatively cytotoxic compound. We also believe that the nanoemulsion particles may shield the toxic albendazole molecules, thereby protecting the cells from direct contact with albendazole. Nonetheless, it is worth noticing that while the MTT assay is a facile and cost-effective approach, it is not ideal for assessing the toxicity of nanoemulsions: By diluting nanoemulsions, they commonly break up. So, the MTT test measures the cytotoxicity of the broken emulsion rather than the nanoemulsion. Therefore, findings from in vitro tests (including the MTT test) should be interpreted cautiously as they are associated with sample dilution (20).

The *in vivo* results show a significant reduction in cyst size and number in the nanoemulsion containing albendazole compared to free albendazole and the nanoemulsion without the drug. Nanoemulsions play a crucial role in enhancing the activity of anti-parasitic agents. In an in vitro report, the spiramycin nanoemulsion showed superior activity against Tachyzoites of Toxoplasma gondii. Specifically, while the nanoemulsion containing 250 µg/ml spiramycin exhibited > 70% mortality, the suspension of spiramycin with the same concentration had < 10% mortality (40). Nanoemulsion containing atovaquone was also reported to be effective against T. gondii in vitro and in vivo. Increased bioavailability, reduced number and size of brain cysts, and better survival rates were observed in infected mice treated with nanoemulsion containing the drug, compared with the nanoemulsion without the drug (30). Curcumin is loaded in nanoemulsions and mouse models' acute and chronic phases of toxoplasmosis (29). Teimouri et al. showed that the scolicidal effect of curcumin nanoemulsion on the mortality rate of protoscoleces that were exposed to 1250 and 625 $\mu g/ml$ of curcumin for 60 min, was 94 and 73.33%, respectively (41).

Several mechanisms have been proposed regarding the fascinating effects of nanoemulsions on drug bioavailability and their permeation through biological membranes: they enhance the solubility of the lipophilic drug (42), form lipoproteins (to facilitate lymphatic transport) (43), and modify the properties of the biological barriers (44, 45). Arguably, nanoemulsions increase its permeation through different biological membranes, including cyst walls. Both mechanisms have played roles in enhancing the scolisidal activity of albendazole. Undoubtedly, further work is required to understand the underlying mechanisms better.

Conclusion

Human echinococcosis is a zoonotic infection resulting from tapeworms belonging to the genus *Echinococcus*. The present study showed significant reductions in both cyst size and number and a lower mortality rate in infected mice treated with albendazole-loaded nanoemulsions compared to those receiving free albendazole. These findings suggest that albendazole-loaded nanoemulsion holds promise as a treatment for hydatidosis, eliminating the need for longterm treatment with free albendazole and reducing its adverse effects.

Acknowledgment

The study was supported by the office of Vice chancellor for research of North Khorasan University of Medical Sciences.

Authors' Contributions

F O, R S, and A A collaborated on the conception and design of the study and co-wrote the manuscript. T M, A E, and P A were involved in conducting the experiments. A A and F O assisted with the statistical analysis and contributed to the manuscript. All authors have read and approved the final version of the manuscript.

Conflicts of Interest

The author(s) declared no potential conflicts of interest concerning this article's research, authorship, and/or publication.

Declaration

We have not used any AI tools or technologies to prepare this manuscript.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was financially supported by a joint grant from North Khorasan University of Medical Sciences, Iran (grant number 970182).

Ethical Statement

The present research was approved by the Ethics Committee of the North Khorasan University of Medical Science, Bojnurd, Iran (Ethical approval code: IR.NKUMS. REC.1397.107).

References

1. Shafiei R, Ghatee M, Jafarzadeh F, Javanshir Z, Karamian M. Genotyping and phylogenetic analysis of unusually located hydatid cysts isolated from humans in north-east Iran. J Helminthol 2020; 94:e64.

2. Zhou T, Xu Y, Gong Y, Yu M, Xu E, Aimaiti W, *et al.* Breakingthen-curing strategy for efficient cystic echinococcosis therapy. Chin Chem Lett 2022; 33:2949-2953.

3. Firouzeh N, Eslaminejad T, Shafiei R, Faridi A, Fasihi Harandi M. Lethal *in vitro* effects of optimized chitosan nanoparticles against protoscoleces of *Echinococcus granulosus*. J Bioact Compat Pol 2021; 36: 237-248.

4. Shafiei R, Mohajerzadeh MS, Masomi HFA, Tavakoli M, Turki H, Firouzeh N. Discordance therapeutic protocol of cystic echinococcosis with WHO guideline: A descriptive study based on liver ultra-sonographic data in North Khorasan province, northeastern of Iran. J Ultrasound Med 2024;43:1279-1287.

5. Moro P, Schantz PM. Echinococcosis: A review. Int J Infect Dis 2009; 13:125-133.

6. Velasco-Tirado V, Alonso-Sardón M, Lopez-Bernus A, Romero-Alegría Á, Burguillo FJ, Muro A, *et al.* Medical treatment of cystic echinococcosis: systematic review and meta-analysis. BMC Infect Dis 2018; 18:1-19.

7. Siracusano A, Teggi A, Ortona E. Human cystic echinococcosis: old problems and new perspectives. Interdiscip Perspect Infect Dis 2009; 2009:474368.

8. Chai J-Y, Jung B-K, Hong S-J. Albendazole and mebendazole as anti-parasitic and anti-cancer agents: An update. Korean J Parasitol 2021; 59:189-225.

9. Falagas ME, Bliziotis IA. Albendazole for the treatment of human echinococcosis: a review of comparative clinical trials. Am J Med Sci 2007; 334:171-179.

10. Venkatesan P. Albendazole. J Antimicrob Chemother 1998; 41:145-147.

11. Dehkordi AB, Sanei B, Yousefi M, Sharafi SM, Safarnezhad F, Jafari R, *et al.* Albendazole and treatment of hydatid cyst: review of the literature. Infect Disord Drug Targets 2019; 19:101-104.

12. Hong S-T. Albendazole and praziquantel: Review and safety monitoring in Korea. Infect Chemother 2018; 50:1-10.

13. Azizi M, Chizzola R, Ghani A, Oroojalian F. Composition at different development stages of the essential oil of four Achillea species grown in Iran. Nat Prod Commun 2010; 5:283-290.

14. Azizi M, Tavana M, Farsi M, Oroojalian F. Yield performance of Lingzhi or Reishi medicinal mushroom, Ganoderma lucidum (W. Curt.: Fr.) P. Karst.(higher Basidiomycetes), using different waste materials as substrates. Int J Med Mushrooms 2012; 14:521-527.

15. Movahedi R, Razmjoue D, Bahmani M, Lysiuk R, Oroojalian F. Eco-friendly green synthesis of silver nanoparticles using daphne mucronata royle seeds extract and the potential antibacterial, antifungal, and scolicidal activities. ChemistrySelect 2024; 9:e202403423.

16. Akhlaghi M, Taebpour M, Sharafaldini M, Javani O, Haghiralsadat BF, Oroojalian F, *et al.* Fabrication, characterization

and evaluation of anti-cancer and antibacterial properties of nanosystems containing *Hedera helix* aqueous extracts. Nanomed J 2022; 9:43-56.

17. Yazdi AM, Hosseini A, Gheibihayat SM, Beygi M, Haghiralsadat BF, Oroojalian F. Characterization, cell toxicity, and antimicrobial activity of a carvacrol-encapsulating nanoliposomal system against *Staphylococcus aureus*, *Pseudomonas aeruginosa*, and *Escherichia coli*. Nanomed J 2024; 11: 93-106.

18. Shoorgashti R, Shahrzad H, Nowroozi S, Ghadamgahi B, Mehrara R, Oroojalian F. Evaluation of the antibacterial and cytotoxic activities of Ag/ZnO nanoparticles loaded polycaprolactone/chitosan composites for dental applications. Nanomed J 2023; 10: 68-76.

19. Gholami Z, Dadmehr M, Jelodar NB, Hosseini M, Parizi AP. One-pot biosynthesis of CdS quantum dots through in vitro regeneration of hairy roots of *Rhaphanus sativus* L. and their apoptosis effect on MCF-7 and AGS cancerous human cell lines. Mater Res Exp 2020; 7:015056.

20. Yousefpoor Y, Esnaashari SS, Baharifar H, Mehrabi M, Amani A. Current challenges ahead in preparation, characterization, and pharmaceutical applications of nanoemulsions. Wiley Interdisciplinary Reviews: Nanomed Nanobiotechnol 2023:e1920. 21. Divanbeigi N, Yousefian M, Etemad L, Azizi M, Ebrahimzadeh A, Oroojalian F, *et al.* Improving the anticancer efficiency of doxorubicin by luteolin nanoemulsion: *In vitro* study. Nanomed J 2023; 10:47-58.

22. Maghbool M, Khosravi T, Vojdani S, Chaijan MR, Esmaeili F, Amani A, *et al.* The effects of eugenol nanoemulsion on pain caused by arteriovenous fistula cannulation in hemodialysis patients: A randomized double-blinded controlled cross-over trial. Complement Ther Med 2020; 52:102440.

23. Valizadeh A, Shirzad M, Pourmand MR, Farahmandfar M, Sereshti H, Amani A. Levofloxacin nanoemulsion gel has a powerful healing effect on infected wound in streptozotocininduced diabetic rats. Drug Deliv Transl Res 2021; 11:292-304.

24. Ammar HO, Salama H, Ghorab M, Mahmoud A. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. Aaps Pharmscitech 2009; 10:808-819.

25. Amani A, York P, Chrystyn H, Clark BJ. Evaluation of a nanoemulsion-based formulation for respiratory delivery of budesonide by nebulizers. Aaps Pharmscitech 2010; 11:1147-1151. 26. Khani S, Keyhanfar F, Amani A. Design and evaluation of oral nanoemulsion drug delivery system of mebudipine. Drug Deliv 2016; 23:2035-2043.

27. Chhabra G, Chuttani K, Mishra AK, Pathak K. Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability. Drug Dev Ind Pharm 2011; 37:907-916.

28. Veerareddy PR, Poluri K, Sistla R, Chaganty S, Vennishetty V. Formulation development and comparative pharmacokinetic evaluation of felodipine nanoemulsion in SD rats. Am J PharmTech Res 2012; 2:931-945.

29. Azami SJ, Teimouri A, Keshavarz H, Amani A, Esmaeili F, Hasanpour H, *et al.* Curcumin nanoemulsion as a novel chemical for the treatment of acute and chronic toxoplasmosis in mice. Int J Nanomedicine 2018; 13:7363-7374.

30. Azami SJ, Amani A, Keshavarz H, Najafi-Taher R, Mohebali M, Faramarzi MA, *et al.* Nanoemulsion of atovaquone as a promising approach for treatment of acute and chronic toxoplasmosis. Eur J Pharm Sci 2018; 117:138-146.

31. Ahmad A, Husain A, Mujeeb M, Khan SA, Najmi AK, Siddique NA, *et al.* A review on therapeutic potential of *Nigella sativa*: A miracle herb. Asian Pac J Trop Biomed 2013; 3:337-352.

32. Pishavar E, Oroojalian F, Ramezani M, Hashemi M. Cholesterolconjugated PEGylated PAMAM as an efficient nanocarrier for plasmid encoding interleukin-12 immunogene delivery toward colon cancer cells. Biotechnol Prog 2020; 36:e2952.

33. Pishavar E, Oroojalian F, Salmasi Z, Hashemi E, Hashemi M.

Recent advances of dendrimer in targeted delivery of drugs and genes to stem cells as cellular vehicles. Biotechnol Prog 2021; 37:e3174.

34. Oroojalian F, Rezayan AH, Shier WT, Abnous K, Ramezani M. Megalin-targeted enhanced transfection efficiency in cultured human HK-2 renal tubular proximal cells using aminoglycosidecarboxyalkyl-polyethylenimine-containing nanoplexes. Int J Pharm 2017; 523:102-120.

35. Oroojalian F, Rezayan AH, Mehrnejad F, Nia AH, Shier WT, Abnous K, *et al.* Efficient megalin targeted delivery to renal proximal tubular cells mediated by modified-polymyxin B-polyethylenimine based nano-gene-carriers. Mater Sci Eng C Mater Biol Appl 2017; 79:770-782.

36. Ahmadnia S, Moazeni M, Mohammadi-Samani S. Hydatid cyst formation in male BALB/c mice following the intraperitoneal injection of live protoscoleces and activated oncospheres: A comparative study. J Parasit Dis 2014; 38:77-80.

37. Rafiei A, Asgarian F, Rahdar M, Jelowdar A, Sabaghan M. Experimental hydatid cyst development in different breeds of mice: A re-evaluation. Biomed Res 2017; 28:1770-1773.

38. Faraji AH, Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem 2009; 17:2950-2962.

39. Petersen JS, Baird SK. Treatment of breast and colon cancer cell lines with anti-he\lmintic benzimidazoles mebendazole or

albendazole results in selective apoptotic cell death. J Cancer Res Clin Oncol 2021; 147:2945-2953.

40. Hashemi-Hafshejani S, Amani A, Azami SJ, Valian HK, Mohebali M, Salimi M, *et al.* Nanoemulsion of spiramycin against tachyzoites of *Toxoplasma gondii*, RH strain: Preparation, toxicology, and efficacy studies. Iran J Public Health 2023; 52:1495-1503.

41. Teimouri A, Jafarpour Azami S, Hashemi Hafshejani S, Ghanimatdan M, Bahreini MS, Alimi R, *et al.* Protoscolicidal effects of curcumin nanoemulsion against protoscoleces of *Echinococcus granulosus*. BMC Complement Med Ther 2023; 23:124-132.

42. Stuchlík M, Zak S. Lipid-based vehicle for oral drug delivery. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2001; 145:17-26.

43. Gershanik T, Benita S. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm 2000; 50:179-188.

44. Shaker DS, Ishak RA, Ghoneim A, Elhuoni MA. Nanoemulsion: A review on mechanisms for the transdermal delivery of hydrophobic and hydrophilic drugs. Sci Pharm 2019; 87:17-50.

45. Aburahma MH, El-Laithy HM, Hamza YE-S. Oral bioavailability enhancement of vinpocetine using self-microemulsifying drug delivery system containing long chain triglycerides: Preparation and *in vitro/in vivo* evaluation. Clin Res Reg Affairs 2010; 27:97-107.